Performance characteristics of a new synthetic APTT reagent

Clinical and Laboratory Haematology

Volumn 20, Issue 5, 1998, Pages 307-313

  Ts'ao, C ^a   Neofotistos, D ^a   Oropeza, M ^a   Rogan, M ^a   Santos, M ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Factor deficiency; Heparin; Lupus anticoagulants; Synthetic APTT reagent

Indexed keywords

BRAIN EXTRACT; DIAGNOSTIC AGENT; HEPARIN; REAGENT;

ANTICOAGULANT THERAPY; ARTICLE; HEMOPHILIA A; HEMOPHILIA B; HEPARINIZATION; HUMAN; MAJOR CLINICAL STUDY; PARTIAL THROMBOPLASTIN TIME; PLASMA; PRIORITY JOURNAL;

COAGULATION PROTEIN DISORDERS; DRUG STABILITY; HEMOPHILIA A; HEMOPHILIA B; HEPARIN; HUMANS; INDICATORS AND REAGENTS; LINEAR MODELS; LUPUS COAGULATION INHIBITOR; PARTIAL THROMBOPLASTIN TIME; SENSITIVITY AND SPECIFICITY;

EID: 0031751589     PISSN: 01419854     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2257.1998.00160.x     Document Type: Article

References (22)

1. Bader R., Mannucci P.M. et al. (1994) Multicentric evaluation of a new PT reagent based on recombinant human tissue factor and synthetic phospholipids. Thrombosis and Haemostasis 71, 292-299.
2. van den Besselaar A.M.H.P., Neuteboom J. & Bertina E.M. (1993) Effect of synthetic phospholipids on the response of the activated partial thomboplastin time to heparin. Blood Coagulation and Fibrinolysis 4, 895-903.
3. van den Besselaar A.M.H.P., Neuteboom J., Meeuwisse-Braun J. & Bertina R.M. (1997) Preparation of lyophilized partial thromboplastin time reagent composed of synthetic phospholipids: usefulness for monitoring heparin theraphy. Clinical Chemistry 43, 1215-1222.
4. Bland J.M. & Altman D.G. (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1, 307-310.
5. Brandt J.T. & Triplett D.A. (1981) Laboratory monitoring of heparin: effect of reagents and instruments on the activated partial thromboplastin time. American Journal of Clinical Pathology 76, 530-537.
6. Brandt J.T., Triplett D.A., Alving B. & Scharrer I. (1995) Criteria for the diagnosis of lupus anticoagulants: an update. Thrombosis and Haemostasis 74, 1185-1190.
7. Denis-Magdelaine A., Flahault A. & Verdy E. (1995) Sensitivity of sixteen APTT reagents for the presence of lupus anticoagulants, Haemostasis 25, 98-105.
8. Finazzi G., Falanga A., Galli M., Cortelazzo S., Remuzzi A. & Barbui T. (1994) Recombinant versus high-sensitivity conventional thromboplastin: a randomized clinical study in patients on oral anticoagulation. Thrombosis and Haemostasis 72, 804-807.
9. Gawoski J.M., Arkin C.F., Bovill T., Brandt J.T., Rock W.A. Jr & Triplett D.A. (1987) The effects of heparin on activated partial thromboplastin time of the College of American Pathologists Survey specimens, Responsiveness, precision and sample effects. Archives of Pathoogy and Laboratory Medicine 111, 785-790.
10. Howarth S. (1993) Activated partial thromboplastin time reagents: an evaluation. British Journal of Biomedical Science 50, 109-113.
11. Kitchen S., Jennings I., Woods T.A.L., Walker I.D. & Preston F.E. (1996a) Two recombinant tissue factor reagents compared to conventional thromboplastins for determination of International Normalized Ratio: A thirty-three-laboratory collaborative study. Thrombosis and Haemostasis 76, 372-376.
12. Kitchen S., Jennings I., Woods T.A.L. & Preston F.E. (1996b) Wide variability in the sensitivity of APTT reagents for monitoring of heparin dosage. Journal of Clinical Pathology 49, 10-14.
13. Kitchen S. & Preston F.E. (1996a) Evaluation of new activated partial thromboplastin time reagent (Synthasil) containing synthetic lipids: Sensitivity to deficiency of factors VIII:C, IX, XI and XII (Abstract). Blood 88 (Suppl.), 76b.
14. Kitchen S. & Preston F.E. (1996b) Evaluation of a new activated partial thromboplastin time reagent (Synthasil) containing synthetic lipids: Sensitivity to heparin and to lupus anticoagulant (Abstract). Blood (Suppl.), 83b.
15. Lemoine S., Demay Y. & Toulon P. (1997) Establishing a therapeutic range for heparin therapy using activated partial thromboplastin time (APTT) performed with reagents containing synthetic phospholipids:Synasil and Synthsfax (Abstract). Thrombosis and Haemostasis 77 (Suppl.), 282.
16. Ray M., Carroll P., Smith I. & Hawson G. (1992) An attempt to standardise activated partial thromboplastin time reagents used to monitor heparin therapy. Blood Coagulation and Fibrinolysis 3, 743-748.
17. Shojania A.M., Tetreault J. & Turnbull G. (1988) The variations between heparin sensitivity of different lots of activated partial thomboplastin reagents produced by the same manufacturer. American Journal of Clinical Pathology 89, 19-23.
18. Stevenson K.J., Easton A.C., Thomson J.M. & Poller L. (1983) Lipid class composition and heparin sensitivity in the activated partial thomboplastin time. Thrombosis and Haemostasis 50, 601-603.
19. Tripodi A., Arbini A., Chantarangkul V. & Mannucci P.M. (1992) Recombinant tissue factor as substitute for conventional thromboplastin in the prothrombin time test. Thrombosis and Haemostasis 67, 42-45.
20. Tripodi A., Chantarangkul V., Braga M. et al. ( 1994) Results of a multicenter study assessing the status of standardization of a recombinant thromboplastin for the control of oral anticoagulant therapy. Thrombosis and Haemostasis 72, 261-267.
21. van der Velde E.A. & Poller L. (1995) The APTT monitoring of heparin - the ISTH/ICSH collaborative study. Thrombosis and Haemostasis 73, 73-81.
22. Woolley A.M., Kitchen S., Brown P.R., Preston F.E. & Malia R.G. (1997) Evaluation of activated partial thromboplastin times (APTT) determined using the Sysmex CA6000 and Synthasil APTT reagent (Abstract). Thrombosis and Haemostasis 77 (Suppl.), 635.